Condition: Focal Onset Seizures · Sponsor: Supernus Pharmaceuticals, Inc.
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
This description comes directly from the study's public registry record.
Supernus Clinical Trials · 240-403-5838 · clinicaltrials@supernus.com
Navid Saeidi, MS · 240-403-5328 · nsaeidi@supernus.com
Always discuss trial participation with your own doctor first.
| Medsol Clinical Research Center | Port Charlotte, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07141329